{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,2]],"date-time":"2025-11-02T16:47:15Z","timestamp":1762102035453},"reference-count":50,"publisher":"Elsevier BV","issue":"24","license":[{"start":{"date-parts":[[2017,5,1]],"date-time":"2017-05-01T00:00:00Z","timestamp":1493596800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2017,5]]},"DOI":"10.1016\/j.vaccine.2017.04.047","type":"journal-article","created":{"date-parts":[[2017,5,5]],"date-time":"2017-05-05T04:30:33Z","timestamp":1493958633000},"page":"3272-3278","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Expression of complete SIV p27 Gag and HIV gp120 engineered outer domains targeted by broadly neutralizing antibodies in live rubella vectors"],"prefix":"10.1016","volume":"35","author":[{"given":"Konstantin","family":"Virnik","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Edmund","family":"Nesti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cody","family":"Dail","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Max","family":"Hockenbury","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yisheng","family":"Ni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Barbara K.","family":"Felber","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William R.","family":"Schief","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ira","family":"Berkower","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2017.04.047_b0005","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1038\/ni.3158","article-title":"Antibody responses to envelope glycoproteins in HIV-1 infection","volume":"16","author":"Burton","year":"2015","journal-title":"Nat Immunol"},{"key":"10.1016\/j.vaccine.2017.04.047_b0010","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1038\/nature07930","article-title":"Broad diversity of neutralizing antibodies isolated from memory B cells in HIV-infected individuals","volume":"458","author":"Scheid","year":"2009","journal-title":"Nature"},{"key":"10.1016\/j.vaccine.2017.04.047_b0015","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1016\/j.immuni.2010.09.011","article-title":"Induction of immunity to human immunodeficiency virus type-1 by vaccination","volume":"33","author":"McElrath","year":"2010","journal-title":"Immunity"},{"key":"10.1016\/j.vaccine.2017.04.047_b0020","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1126\/science.1187659","article-title":"Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1","volume":"329","author":"Wu","year":"2010","journal-title":"Science"},{"key":"10.1016\/j.vaccine.2017.04.047_b0025","doi-asserted-by":"crossref","first-page":"5983","DOI":"10.1128\/JVI.65.11.5983-5990.1991","article-title":"A predominant group-specific neutralizing epitope of human-immunodeficiency-virus type-1 maps to residue-342 to residue-511 of the envelope glycoprotein-Gp120","volume":"65","author":"Berkower","year":"1991","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2017.04.047_b0030","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1128\/JVI.75.2.738-749.2001","article-title":"CD8(+) lymphocytes from simian immunodeficiency virus-infected rhesus macaques recognize 14 different epitopes bound by the major histocompatibility complex class I molecule Mamu-A\u221701: implications for vaccine design and testing","volume":"75","author":"Allen","year":"2001","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2017.04.047_b0035","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1038\/ni.3161","article-title":"Success and failure of the cellular immune response against HIV-1","volume":"16","author":"Migueles","year":"2015","journal-title":"Nat Immunol"},{"key":"10.1016\/j.vaccine.2017.04.047_b0040","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1146\/annurev.med.042508.093728","article-title":"HIV-1 vaccine development after STEP","volume":"61","author":"Barouch","year":"2010","journal-title":"Annu Rev Med"},{"key":"10.1016\/j.vaccine.2017.04.047_b0045","doi-asserted-by":"crossref","first-page":"2083","DOI":"10.1056\/NEJMoa1310566","article-title":"Efficacy trial of a DNA\/rAd5 HIV-1 preventive vaccine","volume":"369","author":"Hammer","year":"2013","journal-title":"New Engl J Med"},{"key":"10.1016\/j.vaccine.2017.04.047_b0050","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1056\/NEJM196007282630406","article-title":"Studies on an attenuated measles-virus vaccine. 6. Clinical, antigenic and prophylactic effects of vaccine in institutionalized children","volume":"263","author":"Krugman","year":"1960","journal-title":"New Engl J Med"},{"key":"10.1016\/j.vaccine.2017.04.047_b0055","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1542\/peds.36.1.40","article-title":"Immunization with inactivated measles virus vaccine - effect of booster dose and response to natural challenge","volume":"36","author":"Karzon","year":"1965","journal-title":"Pediatrics"},{"key":"10.1016\/j.vaccine.2017.04.047_b0060","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.1126\/science.1470917","article-title":"Protective effects of a live attenuated SIV vaccine with a deletion in the nef gene","volume":"258","author":"Daniel","year":"1992","journal-title":"Science"},{"key":"10.1016\/j.vaccine.2017.04.047_b0065","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1038\/5557","article-title":"Live attenuated, multiply deleted simian immunodeficiency virus causes AIDS in infant and adult macaques","volume":"5","author":"Baba","year":"1999","journal-title":"Nat Med"},{"key":"10.1016\/j.vaccine.2017.04.047_b0070","doi-asserted-by":"crossref","first-page":"5453","DOI":"10.1016\/j.vaccine.2012.06.074","article-title":"Live attenuated rubella viral vectors stably express HIV and SIV vaccine antigens while reaching high titers","volume":"30","author":"Virnik","year":"2012","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2017.04.047_b0075","doi-asserted-by":"crossref","first-page":"2119","DOI":"10.1016\/j.vaccine.2013.02.055","article-title":"Enhanced expression of HIV and SIV vaccine antigens in the structural gene region of live attenuated rubella viral vectors and their incorporation into virions","volume":"31","author":"Virnik","year":"2013","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2017.04.047_b0080","series-title":"Vaccines","first-page":"688","article-title":"Rubella vaccine","author":"Plotkin","year":"2013"},{"key":"10.1016\/j.vaccine.2017.04.047_b0085","doi-asserted-by":"crossref","first-page":"743","DOI":"10.4049\/jimmunol.95.4.743","article-title":"Experimental rubella virus infection in the rhesus monkey","volume":"95","author":"Parkman","year":"1965","journal-title":"J Immunol"},{"key":"10.1016\/j.vaccine.2017.04.047_b0090","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1186\/1742-4690-10-99","article-title":"Live attenuated rubella vectors expressing SIV and HIV vaccine antigens replicate and elicit durable immune responses in rhesus macaques","volume":"10","author":"Virnik","year":"2013","journal-title":"Retrovirology"},{"key":"10.1016\/j.vaccine.2017.04.047_b0095","doi-asserted-by":"crossref","first-page":"2167","DOI":"10.1016\/j.vaccine.2015.02.067","article-title":"Recombinant rubella vectors elicit SIV Gag-specific T cell responses with cytotoxic potential in rhesus macaques","volume":"33","author":"Rosati","year":"2015","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2017.04.047_b0100","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1126\/science.1234150","article-title":"Rational HIV immunogen design to target specific germline B cell receptors","volume":"340","author":"Jardine","year":"2013","journal-title":"Science"},{"key":"10.1016\/j.vaccine.2017.04.047_b0105","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1126\/science.aad9195","article-title":"HIV-1 broadly neutralizing antibody precursor B cells revealed by germline-targeting immunogen","volume":"351","author":"Jardine","year":"2016","journal-title":"Science"},{"key":"10.1016\/j.vaccine.2017.04.047_b0110","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1126\/science.1207532","article-title":"Focused evolution of HIV-1 neutralizing antibodies revealed by structures and deep sequencing","volume":"333","author":"Wu","year":"2011","journal-title":"Science"},{"key":"10.1016\/j.vaccine.2017.04.047_b0115","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1038\/nbt.2197","article-title":"B-cell-lineage immunogen design in vaccine development with HIV-1 as a case study","volume":"30","author":"Haynes","year":"2012","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.vaccine.2017.04.047_b0120","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1084\/jem.20122824","article-title":"Engineering HIV envelope protein to activate germline B cell receptors of broadly neutralizing anti-CD4 binding site antibodies","volume":"210","author":"McGuire","year":"2013","journal-title":"J Exp Med"},{"key":"10.1016\/j.vaccine.2017.04.047_b0125","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1089\/aid.1994.10.1651","article-title":"A broadly neutralizing human monoclonal antibody against gp41 of human immunodeficiency virus type 1","volume":"10","author":"Purtscher","year":"1994","journal-title":"AIDS Res Hum Retroviruses"},{"key":"10.1016\/j.vaccine.2017.04.047_b0130","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1126\/science.1213782","article-title":"Increasing the potency and breadth of an HIV antibody by using structure-based rational design","volume":"334","author":"Diskin","year":"2011","journal-title":"Science"},{"key":"10.1016\/j.vaccine.2017.04.047_b0135","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1111\/j.1600-0684.1992.tb00589.x","article-title":"Shared antigenic epitopes of the major core proteins of human and simian immunodeficiency virus isolates","volume":"21","author":"Higgins","year":"1992","journal-title":"J Med Primatol"},{"issue":"Suppl. 3","key":"10.1016\/j.vaccine.2017.04.047_b0140","first-page":"S311","article-title":"Chemical inactivation of retroviral infectivity by targeting nucleocapsid protein zinc fingers: a candidate SIV vaccine","volume":"14","author":"Arthur","year":"1998","journal-title":"AIDS Res Hum Retroviruses"},{"key":"10.1016\/j.vaccine.2017.04.047_b0145","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1006\/viro.2000.0408","article-title":"Infectious cDNA clone of the RA27\/3 vaccine strain of Rubella virus","volume":"273","author":"Pugachev","year":"2000","journal-title":"Virology"},{"key":"10.1016\/j.vaccine.2017.04.047_b0150","first-page":"493","article-title":"A simple method of estimating fifty percent endpoints","volume":"27","author":"Reed","year":"1938","journal-title":"Am J Hygiene"},{"key":"10.1016\/j.vaccine.2017.04.047_b0155","doi-asserted-by":"crossref","first-page":"354","DOI":"10.3390\/vaccines2020354","article-title":"HIV DNA vaccine: stepwise improvements make a difference","volume":"2","author":"Felber","year":"2014","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.vaccine.2017.04.047_b0160","doi-asserted-by":"crossref","first-page":"6763","DOI":"10.1074\/jbc.M112.436675","article-title":"The p40 Subunit of Interleukin (IL)-12 promotes stabilization and export of the p35 subunit: Implications for improved IL-12 cytokine production","volume":"288","author":"Jalah","year":"2013","journal-title":"J Biol Chem"},{"key":"10.1016\/j.vaccine.2017.04.047_b0165","doi-asserted-by":"crossref","first-page":"15547","DOI":"10.1128\/JVI.79.24.15547-15555.2005","article-title":"Attenuation of simian immunodeficiency virus SIVmac239 infection by prophylactic immunization with dna and recombinant adenoviral vaccine vectors expressing Gag","volume":"79","author":"Casimiro","year":"2005","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2017.04.047_b0170","doi-asserted-by":"crossref","first-page":"1830","DOI":"10.1016\/j.vaccine.2011.12.131","article-title":"Inclusion of a CRF01_AE HIV envelope protein boost with a DNA\/MVA prime-boost vaccine: Impact on humoral and cellular immunogenicity and viral load reduction after SHIV-E challenge","volume":"30","author":"Cox","year":"2012","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2017.04.047_b0175","doi-asserted-by":"crossref","first-page":"2209","DOI":"10.1056\/NEJMoa0908492","article-title":"Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand","volume":"361","author":"Rerks-Ngarm","year":"2009","journal-title":"New Eng J Med"},{"key":"10.1016\/j.vaccine.2017.04.047_b0180","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1038\/nature10003","article-title":"Profound early control of highly pathogenic SIV by an effector memory T-cell vaccine","volume":"473","author":"Hansen","year":"2011","journal-title":"Nature"},{"key":"10.1016\/j.vaccine.2017.04.047_b0185","doi-asserted-by":"crossref","first-page":"1237874","DOI":"10.1126\/science.1237874","article-title":"Cytomegalovirus vectors violate CD8+ T cell epitope recognition paradigms","volume":"340","author":"Hansen","year":"2013","journal-title":"Science"},{"key":"10.1016\/j.vaccine.2017.04.047_b0190","doi-asserted-by":"crossref","first-page":"4969","DOI":"10.1016\/j.vaccine.2005.05.034","article-title":"Vaccination of macaques with SIV immunogens delivered by Venezuelan equine encephalitis virus replicon particle vectors followed by a mucosal challenge with SIVsmE660","volume":"23","author":"Johnston","year":"2005","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2017.04.047_b0195","doi-asserted-by":"crossref","first-page":"3699","DOI":"10.1128\/JVI.02255-09","article-title":"Recombinant yellow fever vaccine virus 17D expressing simian immunodeficiency virus SIVmac239 gag induces SIV-specific CD8+ T-cell responses in rhesus macaques","volume":"84","author":"Bonaldo","year":"2010","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2017.04.047_b0200","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/S0092-8674(01)00482-2","article-title":"An effective AIDS vaccine based on live attenuated vesicular stomatitis virus recombinants","volume":"106","author":"Rose","year":"2001","journal-title":"Cell"},{"key":"10.1016\/j.vaccine.2017.04.047_b0205","doi-asserted-by":"crossref","first-page":"3299","DOI":"10.1016\/j.vaccine.2009.01.057","article-title":"Recombinant measles viruses expressing single or multiple antigens of human immunodeficiency virus (HIV-1) induce cellular and humoral immune responses","volume":"27","author":"Liniger","year":"2009","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2017.04.047_b0210","doi-asserted-by":"crossref","first-page":"10811","DOI":"10.1128\/JVI.74.22.10811-10815.2000","article-title":"Development of a rubella virus vaccine expression vector: use of a picornavirus internal ribosome entry site increases stability of expression","volume":"74","author":"Pugachev","year":"2000","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2017.04.047_b0215","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1126\/science.aac5894","article-title":"HIV-1 VACCINES. Priming a broadly neutralizing antibody response to HIV-1 using a germline-targeting immunogen","volume":"349","author":"Jardine","year":"2015","journal-title":"Science"},{"key":"10.1016\/j.vaccine.2017.04.047_b0220","doi-asserted-by":"crossref","first-page":"e1005815","DOI":"10.1371\/journal.ppat.1005815","article-title":"Minimally mutated HIV-1 broadly neutralizing antibodies to guide reductionist vaccine design","volume":"12","author":"Jardine","year":"2016","journal-title":"PLoS Pathog"},{"issue":"1459\u201370","key":"10.1016\/j.vaccine.2017.04.047_b0225","first-page":"e11","article-title":"Tailored immunogens direct affinity maturation toward HIV neutralizing antibodies","volume":"166","author":"Briney","year":"2016","journal-title":"Cell"},{"issue":"6307","key":"10.1016\/j.vaccine.2017.04.047_b0230","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1126\/science.aah3945","article-title":"Priming HIV-1 broadly neutralizing antibody precursors in human Ig loci transgenic mice","volume":"353","author":"Sok","year":"2016","journal-title":"Science"},{"key":"10.1016\/j.vaccine.2017.04.047_b0235","doi-asserted-by":"crossref","first-page":"e1003618","DOI":"10.1371\/journal.ppat.1003618","article-title":"A next-generation cleaved, soluble HIV-1 Env trimer, BG505 SOSIP.664 gp140, expresses multiple epitopes for broadly neutralizing but not non-neutralizing antibodies","volume":"9","author":"Sanders","year":"2013","journal-title":"PLoS Pathog"},{"key":"10.1016\/j.vaccine.2017.04.047_b0240","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1038\/nsmb.3051","article-title":"Crystal structure, conformational fixation and entry-related interactions of mature ligand-free HIV-1 Env","volume":"22","author":"Kwon","year":"2015","journal-title":"Nat Struct Mol Biol"},{"key":"10.1016\/j.vaccine.2017.04.047_b0245","doi-asserted-by":"crossref","first-page":"1828","DOI":"10.1056\/NEJMoa1302976","article-title":"Absence of detectable HIV-1 viremia after treatment cessation in an infant","volume":"369","author":"Persaud","year":"2013","journal-title":"New Eng J Med"},{"key":"10.1016\/j.vaccine.2017.04.047_b0250","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1056\/NEJMc1413931","article-title":"Viremic relapse after HIV-1 remission in a perinatally infected child","volume":"372","author":"Luzuriaga","year":"2015","journal-title":"New Eng J Med"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X1730539X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X1730539X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,8,23]],"date-time":"2023-08-23T12:20:22Z","timestamp":1692793222000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X1730539X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,5]]},"references-count":50,"journal-issue":{"issue":"24","published-print":{"date-parts":[[2017,5]]}},"alternative-id":["S0264410X1730539X"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2017.04.047","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2017,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Expression of complete SIV p27 Gag and HIV gp120 engineered outer domains targeted by broadly neutralizing antibodies in live rubella vectors","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2017.04.047","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}